HLA-E contributes to an immune-inhibitory phenotype of glioblastoma stem-like cells

Arlettaz, 2004, Activating CD94:NKG2C and inhibitory CD94:NKG2A receptors are expressed by distinct subsets of committed CD8+ TCR alphabeta lymphocytes, Eur. J. Immunol., 34, 3456, 10.1002/eji.200425210 Bar, 2010, Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres, Am. J. Pathol., 177, 1491, 10.2353/ajpath.2010.091021 Beier, 2011, CD133 negative cancer stem cells in glioblastoma, Front. Biosci. (Elite Ed.), 3, 701, 10.2741/e280 Bertone, 1999, Transforming growth factor-beta-induced expression of CD94/NKG2A inhibitory receptors in human T lymphocytes, Eur. J. Immunol., 29, 23, 10.1002/(SICI)1521-4141(199901)29:01<23::AID-IMMU23>3.0.CO;2-Y Bianchini, 2006, Comparative study of gene expression by cDNA microarray in human colorectal cancer tissues and normal mucosa, Int. J. Oncol., 29, 83 Castriconi, 2009, NK cells recognize and kill human glioblastoma cells with stem cell-like properties, J. Immunol., 182, 3530, 10.4049/jimmunol.0802845 de Kruijf, 2010, HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients, J. Immunol., 185, 7452, 10.4049/jimmunol.1002629 Derre, 2006, Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells, J. Immunol., 177, 3100, 10.4049/jimmunol.177.5.3100 Di Tomaso, 2010, Immunobiological characterization of cancer stem cells isolated from glioblastoma patients, Clin. Cancer Res., 16, 800, 10.1158/1078-0432.CCR-09-2730 Dietrich, 2011, T-cell immunotherapy for malignant glioma: toward a combined approach, Curr. Opin. Oncol., 22, 604, 10.1097/CCO.0b013e32833dead8 Eisele, 2006, TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells, Brain, 129, 2416, 10.1093/brain/awl205 Facoetti, 2005, Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors, Clin. Cancer Res., 11, 8304, 10.1158/1078-0432.CCR-04-2588 Friese, 2003, MICA/NKG2D-mediated immunogene therapy of experimental gliomas, Cancer Res., 63, 8996 Friese, 2004, The innate immune response in the central nervous system and its role in glioma immune surveillance, Onkologie, 27, 487, 10.1159/000080371 Gooden, 2011, HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8 T lymphocytes, Proc. Natl. Acad. Sci. U. S. A., 108, 10656, 10.1073/pnas.1100354108 Griguer, 2008, CD133 is a marker of bioenergetic stress in human glioma, PLoS One, 3, e3655, 10.1371/journal.pone.0003655 Gunther, 2008, Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria, Oncogene, 27, 2897, 10.1038/sj.onc.1210949 Han, 2009, Gamma interferon-mediated superinduction of B7-H1 in PTEN-deficient glioblastoma: a paradoxical mechanism of immune evasion, Neuroreport, 20, 1597, 10.1097/WNR.0b013e32833188f7 Haque, 2007, Emerging role of combination of all-trans retinoic acid and interferon-gamma as chemoimmunotherapy in the management of human glioblastoma, Neurochem. Res., 32, 2203, 10.1007/s11064-007-9420-z Heimberger, 2011, Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?, Neuro Oncol., 13, 3, 10.1093/neuonc/noq169 Hemmati, 2003, Cancerous stem cells can arise from pediatric brain tumors, Proc. Natl. Acad. Sci. U. S. A., 100, 15178, 10.1073/pnas.2036535100 Ieta, 2008, Biological and genetic characteristics of tumor-initiating cells in colon cancer, Ann. Surg. Oncol., 15, 638, 10.1245/s10434-007-9605-3 Kane, 2010, Interferon-gamma in brain tumor immunotherapy, Neurosurg. Clin. N. Am., 21, 77, 10.1016/j.nec.2009.08.011 Kren, 2010, Production of immune-modulatory nonclassical molecules HLA-G and HLA-E by tumor infiltrating ameboid microglia/macrophages in glioblastomas: a role in innate immunity?, J. Neuroimmunol., 220, 131, 10.1016/j.jneuroim.2010.01.014 Kren, 2011, Expression of immune-modulatory molecules HLA-G and HLA-E by tumor cells in glioblastomas: an unexpected prognostic significance?, Neuropathology, 31, 129, 10.1111/j.1440-1789.2010.01149.x Lee-MacAry, 2001, Development of a novel flow cytometric cell-mediated cytotoxicity assay using the fluorophores PKH-26 and TO-PRO-3 iodide, J. Immunol. Methods, 252, 83, 10.1016/S0022-1759(01)00336-2 Levy, 2008, Human leukocyte antigen-E protein is overexpressed in primary human colorectal cancer, Int. J. Oncol., 32, 633 Malmberg, 2002, IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism, J. Clin. Invest., 110, 1515, 10.1172/JCI0215564 Marin, 2003, Analysis of HLA-E expression in human tumors, Immunogenetics, 54, 767, 10.1007/s00251-002-0526-9 Mittelbronn, 2007, Elevated HLA-E levels in human glioblastomas but not in grade I to III astrocytomas correlate with infiltrating CD8+ cells, J. Neuroimmunol., 189, 50, 10.1016/j.jneuroim.2007.07.002 Nguyen, 2009, HLA-E upregulation on IFN-gamma-activated AML blasts impairs CD94/NKG2A-dependent NK cytolysis after haplo-mismatched hematopoietic SCT, Bone Marrow Transplant., 43, 693, 10.1038/bmt.2008.380 Palmisano, 2005, HLA-E surface expression is independent of the availability of HLA class I signal sequence-derived peptides in human tumor cell lines, Hum. Immunol., 66, 1, 10.1016/j.humimm.2004.10.006 Pietra, 2003, HLA-E-restricted recognition of cytomegalovirus-derived peptides by human CD8+ cytolytic T lymphocytes, Proc. Natl. Acad. Sci. U. S. A., 100, 10896, 10.1073/pnas.1834449100 Pietra, 2009, HLA-E and HLA-E-bound peptides: recognition by subsets of NK and T cells, Curr. Pharm. Des., 15, 3336, 10.2174/138161209789105207 Robertson, 1996, Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia, Exp. Hematol., 24, 406 Schulte, 2009, The HLA-E(R)/HLA-E(R) genotype affects the natural course of hepatitis C virus (HCV) infection and is associated with HLA-E-restricted recognition of an HCV-derived peptide by interferon-gamma-secreting human CD8(+) T cells, J. Infect. Dis., 200, 1397, 10.1086/605889 Sensi, 2009, Peptides with dual binding specificity for HLA-A2 and HLA-E are encoded by alternatively spliced isoforms of the antioxidant enzyme peroxiredoxin 5, Int. Immunol., 21, 257, 10.1093/intimm/dxn141 Singh, 2004, Identification of human brain tumour initiating cells, Nature, 432, 396, 10.1038/nature03128 Tabatabai, 2011, Glioblastoma stem cells, Cell Tissue Res., 343, 459, 10.1007/s00441-010-1123-0 Ulbrecht, 1999, Cell surface expression of HLA-E: interaction with human beta2-microglobulin and allelic differences, Eur. J. Immunol., 29, 537, 10.1002/(SICI)1521-4141(199902)29:02<537::AID-IMMU537>3.0.CO;2-6 Wada, 2004, The inhibitory NK cell receptor CD94/NKG2A and the activating receptor CD94/NKG2C bind the top of HLA-E through mostly shared but partly distinct sets of HLA-E residues, Eur. J. Immunol., 34, 81, 10.1002/eji.200324432 Wei, 2010, Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway, Mol. Cancer Ther., 9, 67, 10.1158/1535-7163.MCT-09-0734 Wei, 2010, Glioma-associated cancer-initiating cells induce immunosuppression, Clin. Cancer Res., 16, 461, 10.1158/1078-0432.CCR-09-1983 Wischhusen, 2005, HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: implications for immune escape in vivo, J. Neuropathol. Exp. Neurol., 64, 523, 10.1093/jnen/64.6.523 Wischhusen, 2007, Immune-refractory cancers and their little helpers—an extended role for immunetolerogenic MHC molecules HLA-G and HLA-E?, Semin. Cancer Biol., 17, 459, 10.1016/j.semcancer.2007.07.005